Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.

Giuseppe ManciaFederico ReaMonica LudergnaniGiovanni ApoloneGiovanni Corrao

Published in: The New England journal of medicine (2020)

In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19.

Keyphrases

angiotensin converting enzyme
angiotensin ii
coronavirus disease
sars cov
cardiovascular disease
risk factors
type diabetes
respiratory syndrome coronavirus
metabolic syndrome